Literature DB >> 25481266

Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

Charlie Garnett-Benson1, James W Hodge2, Sofia R Gameiro3.   

Abstract

Radiation therapy (RT) is widely used with curative or palliative intent in the clinical management of multiple cancers. Although mainly aimed at direct tumor cell killing, mounting evidence suggests that radiation can alter the tumor to become an immunostimulatory milieu. Data suggest that the immunogenic effects of radiation can be exploited to promote synergistic antitumor effects in combination with immunotherapeutic agents. We review concepts associated with the immunogenic consequences of RT and highlight how preclinical findings are translating into clinical benefit for patients receiving combination regimens of RT and therapeutic cancer vaccines. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25481266      PMCID: PMC4258617          DOI: 10.1016/j.semradonc.2014.07.002

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  56 in total

1.  Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.

Authors:  Raquibul Hannan; Huagang Zhang; Anu Wallecha; Reshma Singh; Laibin Liu; Patrice Cohen; Alan Alfieri; John Rothman; Chandan Guha
Journal:  Cancer Immunol Immunother       Date:  2012-05-27       Impact factor: 6.968

2.  Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.

Authors:  Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

3.  Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

Authors:  James L Gulley; Christopher R Heery; Ravi A Madan; Beatriz A Walter; Maria J Merino; William L Dahut; Kwong-Yok Tsang; Jeffrey Schlom; Peter A Pinto
Journal:  Cancer Immunol Immunother       Date:  2013-07-09       Impact factor: 6.968

4.  Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.

Authors:  Kwan-Hwa Chi; Shih-Jen Liu; Chung-Pin Li; Hsu-Ping Kuo; Yu-Shan Wang; Yee Chao; Shih-Liang Hsieh
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

Review 5.  TRICOM vector based cancer vaccines.

Authors:  Charlie T Garnett; John W Greiner; Kwong-Yok Tsang; Chie Kudo-Saito; Douglas W Grosenbach; Mala Chakraborty; James L Gulley; Philip M Arlen; Jeffrey Schlom; James W Hodge
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

6.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

7.  Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.

Authors:  Oana Draghiciu; Mateusz Walczak; Baukje Nynke Hoogeboom; Kees L M C Franken; Kees J M Melief; Hans W Nijman; Toos Daemen
Journal:  Int J Cancer       Date:  2013-09-04       Impact factor: 7.396

8.  4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.

Authors:  Beom K Choi; Jun S Bae; Eun M Choi; Woo J Kang; Shimon Sakaguchi; Dass S Vinay; Byoung S Kwon
Journal:  J Leukoc Biol       Date:  2003-12-23       Impact factor: 4.962

9.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.

Authors:  Anna R Kwilas; Renee N Donahue; Michael B Bernstein; James W Hodge
Journal:  Front Oncol       Date:  2012-09-06       Impact factor: 6.244

Review 10.  Trial Watch: Anticancer radioimmunotherapy.

Authors:  Erika Vacchelli; Ilio Vitale; Eric Tartour; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-03       Impact factor: 8.110

View more
  15 in total

1.  Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.

Authors:  Franziska Eckert; Philipp Schaedle; Daniel Zips; Barbara Schmid-Horch; Hans-Georg Rammensee; Cihan Gani; Cécile Gouttefangeas
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 2.  Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Authors:  Maureen L Aliru; Jonathan E Schoenhals; Bhanu P Venkatesulu; Clark C Anderson; Hampartsoum B Barsoumian; Ahmed I Younes; Lakshmi S K Mahadevan; Melinda Soeung; Kathryn E Aziz; James W Welsh; Sunil Krishnan
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

Review 3.  Immunomodulatory effects of radiation: what is next for cancer therapy?

Authors:  Anita Kumari; Samantha S Simon; Tomika D Moody; Charlie Garnett-Benson
Journal:  Future Oncol       Date:  2015-12-01       Impact factor: 3.404

Review 4.  Using immunotherapy to boost the abscopal effect.

Authors:  Wilfred Ngwa; Omoruyi Credit Irabor; Jonathan D Schoenfeld; Jürgen Hesser; Sandra Demaria; Silvia C Formenti
Journal:  Nat Rev Cancer       Date:  2018-02-16       Impact factor: 60.716

5.  Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer.

Authors:  Megan Morisada; Ellen C Moore; Rachel Hodge; Jay Friedman; Harrison A Cash; James W Hodge; James B Mitchell; Clint T Allen
Journal:  Oral Oncol       Date:  2017-06-10       Impact factor: 5.337

6.  Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.

Authors:  Peter Joseph DeMaria; Marijo Bilusic; Deric M Park; Christopher R Heery; Renee N Donahue; Ravi A Madan; Mohammad Hadi Bagheri; Julius Strauss; Victoria Shen; Jennifer L Marté; Seth M Steinberg; Jeffrey Schlom; Mark R Gilbert; James L Gulley
Journal:  Oncologist       Date:  2021-03-09

7.  NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.

Authors:  Priscilla S Simon; Kankana Bardhan; May R Chen; Amy V Paschall; Chunwan Lu; Roni J Bollag; Feng-Chong Kong; JianYue Jin; Feng-Ming Kong; Jennifer L Waller; Raphael E Pollock; Kebin Liu
Journal:  Oncotarget       Date:  2016-04-26

8.  Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.

Authors:  Anita Kumari; Charlie Garnett-Benson
Journal:  BMC Res Notes       Date:  2016-02-13

9.  Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.

Authors:  Gilda G Hillman; Lyndsey A Reich; Shoshana E Rothstein; Lisa M Abernathy; Matthew D Fountain; Kali Hankerd; Christopher K Yunker; Joseph T Rakowski; Eric Quemeneur; Philippe Slos
Journal:  J Immunother Cancer       Date:  2017-01-17       Impact factor: 13.751

10.  Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.

Authors:  Marka R Crittenden; Lauren Zebertavage; Gwen Kramer; Shelly Bambina; David Friedman; Victoria Troesch; Tiffany Blair; Jason R Baird; Alejandro Alice; Michael J Gough
Journal:  Sci Rep       Date:  2018-05-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.